Acute lymphoblastic leukemia in a β-thalassemia intermedia child: A case report

BACKGROUND β-thalassemia intermedia (βTI) is one of the hemoglobinopathies. It constitutes 10% of β-thalassemia cases yet being associated with a better quality of life than β-thalassemia major (βTM). CASE SUMMARY We recently reported the first case of acute lymphoblastic leukemia (ALL) from Egypt in a child with βTM, and we herein report the first case of ALL from Egypt in a child with βTI. In this report, literature was reviewed for cases of malignancies associated with βTI and the possible factors underling the relationship between the two entities. CONCLUSION We stress that physicians should have a high index of suspicion of malignancies in thalassemia patients if they present with any suggestive symptoms or signs.

[1]  Beta Thalassemia , 2020, Definitions.

[2]  M. Cappellini,et al.  A higher prevalence of hematologic malignancies in patients with thalassemia: Background and culprits , 2017, American journal of hematology.

[3]  N. Kamal,et al.  First Report of Acute Lymphoblastic Leukemia in an Egyptian Child with β-Thalassemia Major , 2015, Hemoglobin.

[4]  D. Tuğcu,et al.  Thalassemia Intermedia and Acute Lymphoblastic Leukemia: Is it a Coincidental Double Diagnosis? , 2014, Turkish journal of haematology : official journal of Turkish Society of Haematology.

[5]  S. Alavi,et al.  Hematological malignancies complicating β-thalassemia syndromes: a single center experience , 2013, Blood research.

[6]  R. Ware,et al.  Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: Results from the BABY‐HUG phase III clinical trial , 2012, Pediatric blood & cancer.

[7]  S. Monti,et al.  Malignancies in β-Thalassemia Patients: First Description of Two Cases of Thyroid Cancer and Review of the Literature , 2011, Hemoglobin.

[8]  F. Valenza,et al.  Hepatocellular carcinoma in patients with thalassaemia syndromes: clinical characteristics and outcome in a long term single centre experience , 2010, British journal of haematology.

[9]  Soso Fragatou,et al.  Incidence of Hepatocellular Carcinoma in a Thalassemia Unit , 2010, Hemoglobin.

[10]  M. Karimi,et al.  Malignancies in patients with β‐thalassemia major and β‐thalassemia intermedia: A multicenter study in Iran , 2009, Pediatric blood & cancer.

[11]  A. Vassou,et al.  Malignancies in β‐thalassemia patients: a single‐center experience and a concise review of the literature , 2008, International journal of laboratory hematology.

[12]  A. Taher,et al.  β‐thalassemia intermedia and hodgkin lymphoma , 2006 .

[13]  A. Mancuso,et al.  A Prospective Study of Hepatocellular Carcinoma Incidence in Thalassemia , 2006, Hemoglobin.

[14]  M. Cappellini,et al.  Hepatocellular carcinoma in the thalassaemia syndromes , 2004, British journal of haematology.

[15]  A. Taher,et al.  β-THALASSEMIA INTERMEDIA AND NON-HODGKIN'S LYMPHOMA , 2002 .

[16]  M. Cappellini,et al.  Hepatocellular carcinoma in hepatitis-negative patients with thalassemia intermedia: a closer look at the role of siderosis. , 2013, Annals of hepatology.

[17]  A. Taher,et al.  Beta-thalassemia intermedia and Hodgkin lymphoma. , 2006, American journal of hematology.

[18]  A. Taher,et al.  Beta-thalassemia intermedia and non-Hodgkin's lymphoma. , 2002, Hemoglobin.